Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Cancer Res. 2017 Jan 15;77(2):434-447. doi: 10.1158/0008-5472.CAN-16-2060. Epub 2016 Nov 21.
The polo family serine threonine kinase Plk4 has been proposed as a therapeutic target in advanced cancers based on increased expression in primary human cancers, facilitation of tumor growth in murine xenograft models, and centrosomal amplification induced by its overexpression. However, both the causal link between these phenomena and the feasibility of selective Plk4 inhibition remain unclear. Here we characterize Plk4-dependent cancer cell migration and invasion as well as local invasion and metastasis of cancer xenografts. Plk4 depletion suppressed cancer invasion and induced an epithelial phenotype in poorly differentiated breast cancer cells. In an unbiased BioID screen for Plk4 interactors, we identified members of the Arp2/3 complex and confirmed a physical and functional interaction between Plk4 and Arp2 in mediating Plk4-driven cancer cell movement. This interaction is mediated through the Plk4 Polo-box 1-Polo-box 2 domain and results in phosphorylation of Arp2 at the T237/T238 activation site, which is required for Plk4-driven cell movement. Our results validate Plk4 as a therapeutic target in cancer patients and reveal a new role for Plk4 in regulating Arp2/3-mediated actin cytoskeletal rearrangement. Cancer Res; 77(2); 434-47. ©2016 AACR.
丝氨酸苏氨酸激酶 Polo 家族的 Plk4 已被提议作为先进癌症的治疗靶点,其依据为:在原发性人类癌症中表达增加、在小鼠异种移植模型中促进肿瘤生长、以及其过表达诱导中心体扩增。然而,这些现象之间的因果关系以及选择性 Plk4 抑制的可行性仍不清楚。在此,我们描述了 Plk4 依赖性癌细胞迁移和侵袭,以及癌症异种移植物的局部侵袭和转移。Plk4 耗竭抑制了癌症侵袭,并诱导分化不良的乳腺癌细胞呈现上皮表型。在针对 Plk4 相互作用体的无偏 BioID 筛选中,我们鉴定出了 Arp2/3 复合物的成员,并证实了 Plk4 和 Arp2 之间在介导 Plk4 驱动的癌细胞运动中的物理和功能相互作用。这种相互作用是通过 Plk4 的 Polo 框 1-Polo 框 2 结构域介导的,并导致 Arp2 在 T237/T238 激活位点发生磷酸化,这是 Plk4 驱动的细胞运动所必需的。我们的研究结果验证了 Plk4 作为癌症患者的治疗靶点,并揭示了 Plk4 在调节 Arp2/3 介导的肌动蛋白细胞骨架重排中的新作用。Cancer Res; 77(2); 434-47. ©2016 AACR.